The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.
Animals
Antibodies, Monoclonal, Humanized
/ chemistry
Antigens, CD19
/ metabolism
Antineoplastic Agents
/ chemistry
Cell Line, Tumor
Disease Models, Animal
Dose-Response Relationship, Drug
Female
Humans
Immunoconjugates
/ chemistry
Leukemia
/ drug therapy
Lymphoma
/ drug therapy
Maytansine
/ analogs & derivatives
Mice
Treatment Outcome
Xenograft Model Antitumor Assays
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
03
11
2018
accepted:
07
02
2019
pubmed:
9
2
2019
medline:
17
6
2020
entrez:
9
2
2019
Statut:
ppublish
Résumé
Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development. Here, we present huB4-DGN462, a novel ADC based on the SAR3419 anti-CD19 antibody linked
Identifiants
pubmed: 30733273
pii: haematol.2018.211011
doi: 10.3324/haematol.2018.211011
pmc: PMC6669148
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antigens, CD19
0
Antineoplastic Agents
0
Immunoconjugates
0
Maytansine
14083FR882
coltuximab ravtansine
MRS84YT9L2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1633-1639Informations de copyright
Copyright© 2019 Ferrata Storti Foundation.
Références
Blood. 2009 Apr 30;113(18):4352-61
pubmed: 19147785
Clin Cancer Res. 2009 Jun 15;15(12):4038-45
pubmed: 19509168
J Med Chem. 2011 May 26;54(10):3606-23
pubmed: 21517041
Clin Cancer Res. 2011 Oct 15;17(20):6448-58
pubmed: 22003072
J Clin Oncol. 2012 Aug 1;30(22):2776-82
pubmed: 22753910
Blood. 2013 Nov 14;122(20):3500-10
pubmed: 24002446
Clin Cancer Res. 2014 Jan 1;20(1):213-20
pubmed: 24132920
Clin Cancer Res. 2015 Jul 15;21(14):3298-306
pubmed: 25840969
Mol Pharm. 2015 Jun 1;12(6):1703-16
pubmed: 25856201
Clin Cancer Res. 2015 Sep 15;21(18):4035-9
pubmed: 26374073
Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):139-45
pubmed: 26775883
Br J Haematol. 2016 Jun;173(5):722-30
pubmed: 27010483
Mol Cancer Ther. 2016 Aug;15(8):1870-8
pubmed: 27216304
Nat Rev Drug Discov. 2017 May;16(5):315-337
pubmed: 28303026
Neoplasia. 2017 Sep;19(9):661-671
pubmed: 28753442
Blood. 2017 Nov 2;130(18):2018-2026
pubmed: 28903943
Ann Oncol. 2017 Dec 1;28(12):3083-3091
pubmed: 29045509
Clin Cancer Res. 2018 Jan 1;24(1):120-129
pubmed: 29066507
Ann Oncol. 2018 Feb 1;29(2):332-340
pubmed: 29206891
Blood. 2018 Mar 8;131(10):1094-1105
pubmed: 29298756
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Ann Oncol. 2018 May 1;29(5):1266-1272
pubmed: 29444231
Clin Cancer Res. 2018 Jul 1;24(13):2993-2998
pubmed: 29535129
Mol Cancer Ther. 2018 Jun;17(6):1271-1279
pubmed: 29588393
Ann Oncol. 2018 May 1;29(5):1120-1129
pubmed: 29659676
Blood. 2018 Aug 23;132(8):777-781
pubmed: 29914976
Oncologist. 2018 Nov;23(11):1366-1371
pubmed: 30018129
Clin Cancer Res. 2019 Jan 15;25(2):473-477
pubmed: 30254079
Clin Cancer Res. 2019 Feb 15;25(4):1142-1146
pubmed: 30309857
Clin Cancer Res. 2019 Mar 15;25(6):1702-1708
pubmed: 30413526
Hematol Oncol. 2019 Aug;37(3):233-239
pubmed: 30427551